243 related articles for article (PubMed ID: 26398246)
21. Epidermal cyst formation and hyperkeratosis in a patient treated with vismodegib for locally advanced Basal cell carcinoma.
Reinders MG; Brinkhuizen T; Soetekouw PM; Kelleners-Smeets NW; Hamid MA; Mosterd K
Acta Derm Venereol; 2015 May; 95(5):618-9. PubMed ID: 25425396
[No Abstract] [Full Text] [Related]
22. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
23. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
Lyseng-Williamson KA; Keating GM
Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
[TBL] [Abstract][Full Text] [Related]
24. Regression of a basal cell carcinoma infiltrating the brain after vismodegib therapy.
Kaehler KC; Gutzmer R; Egberts F; Hauschild A
J Dtsch Dermatol Ges; 2014 Oct; 12(10):906-7. PubMed ID: 25041591
[No Abstract] [Full Text] [Related]
25. Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449).
Meani RE; Lim SW; Chang AL; Kelly JW
Australas J Dermatol; 2014 Aug; 55(3):218-21. PubMed ID: 25117162
[TBL] [Abstract][Full Text] [Related]
26. Vismodegib in basal cell carcinoma.
Amaria RN; Bowles DW; Lewis KD; Jimeno A
Drugs Today (Barc); 2012 Jul; 48(7):459-67. PubMed ID: 22844657
[TBL] [Abstract][Full Text] [Related]
27. Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus Syndrome.
Ozgur OK; Yin V; Chou E; Ball S; Kies M; William WN; Migden M; Thuro BA; Esmaeli B
Am J Ophthalmol; 2015 Aug; 160(2):220-227.e2. PubMed ID: 25935097
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical markers of advanced basal cell carcinoma: CD56 is associated with a lack of response to vismodegib.
Castillo JM; Knol AC; Nguyen JM; Khammari A; Saint-Jean M; Dreno B
Eur J Dermatol; 2016 Oct; 26(5):452-459. PubMed ID: 27346829
[TBL] [Abstract][Full Text] [Related]
29. Vismodegib (ERIVEDGE°) In basal cell carcinoma: too many unknowns.
Prescrire Int; 2015 Jan; 24(156):11-4. PubMed ID: 25729822
[TBL] [Abstract][Full Text] [Related]
30. Vismodegib resistance in basal cell carcinoma: not a smooth fit.
Ridky TW; Cotsarelis G
Cancer Cell; 2015 Mar; 27(3):315-6. PubMed ID: 25759014
[TBL] [Abstract][Full Text] [Related]
31. [Vismodegib Therapy for Periocular Basal Cell Carcinoma].
Keserü M; Green S; Dulz S
Klin Monbl Augenheilkd; 2017 Jan; 234(1):64-69. PubMed ID: 28135752
[No Abstract] [Full Text] [Related]
32. Treatment of margin positive basal cell carcinoma with vismodegib: case report and consideration of treatment options and their implications.
Bayers S; Kapp DL; Beer KR; Slavin B
J Drugs Dermatol; 2013 Oct; 12(10 Suppl):s147-50. PubMed ID: 24085060
[TBL] [Abstract][Full Text] [Related]
33. Compassionate use of vismodegib and adjuvant radiotherapy in the treatment of multiple locally advanced and inoperable basal cell carcinomas and squamous cell carcinomas of the skin.
Gathings RM; Orscheln CS; Huang WW
J Am Acad Dermatol; 2014 Apr; 70(4):e88-e89. PubMed ID: 24629372
[No Abstract] [Full Text] [Related]
34. Outcomes of Vismodegib for Periocular Locally Advanced Basal Cell Carcinoma From an Open-label Trial.
Ben Ishai M; Tiosano A; Fenig E; Ben Simon G; Yassur I
JAMA Ophthalmol; 2020 Jul; 138(7):749-755. PubMed ID: 32407451
[TBL] [Abstract][Full Text] [Related]
35. Vismodegib as eye-sparing adjuvant treatment for orbital basal cell carcinoma.
Kahana A; Worden FP; Elner VM
JAMA Ophthalmol; 2013 Oct; 131(10):1364-6. PubMed ID: 23907144
[No Abstract] [Full Text] [Related]
36. Vismodegib and surgery combined - effective treatment of locally advanced basal cell carcinoma.
Paulsen JF; Øregaard JS; Nielsen AL; Gehl J; Venzo A
Acta Oncol; 2016 Dec; 55(12):1492-1494. PubMed ID: 27448604
[No Abstract] [Full Text] [Related]
37. [Vismodegib in metastasized basal cell carcinoma].
Reinders MG; Dirix L; Mosterd K; van Doorn R
Ned Tijdschr Geneeskd; 2013; 157(12):A6011. PubMed ID: 23515044
[TBL] [Abstract][Full Text] [Related]
38. Two different scenarios of squamous cell carcinoma within advanced Basal cell carcinomas: cases illustrating the importance of serial biopsy during vismodegib usage.
Zhu GA; Sundram U; Chang AL
JAMA Dermatol; 2014 Sep; 150(9):970-3. PubMed ID: 24740281
[TBL] [Abstract][Full Text] [Related]
39. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
[TBL] [Abstract][Full Text] [Related]
40. Vismodegib and the Hedgehog Pathway Inhibitors: A Historical Perspective to Current Clinical Application.
Tang JC; Hanke CW; Caro I
J Drugs Dermatol; 2018 May; 17(5):506-508. PubMed ID: 29742180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
